Status:
COMPLETED
Retrospective Study to Describe the Real-world Treatment Patterns and Associated Clinical Outcomes in Patients With Metastatic Castration-resistant Prostates Cancer
Lead Sponsor:
AstraZeneca
Conditions:
Metastatic Castration-resistant Prostates Cancer
Eligibility:
MALE
18+ years
Brief Summary
This is a multi-country, multi-centre, retrospective, non-interventional cohort study planned to include patients diagnosed with mCRPC between 01 January 2016 and 31 December 2018, who have received a...
Detailed Description
This is a multi-country, multi-centre, retrospective, non-interventional cohort study planned to include patients diagnosed with mCRPC between 01 January 2016 and 31 December 2018, who have received a...
Eligibility Criteria
Inclusion
- Male patients ≥18 years of age OR legal age of being an adult in the country as per local regulations 2. Patient or next of kin/legal representative (for deceased patients at study entry, unless a waiver is granted) willing and able to provide written informed consent according to the local regulations 3. Patients with a diagnosis of metastatic (stage IV) mCRPC, confirmed by either biopsy of a metastatic tumour site or by history of biopsy-proven localized disease and evidence of metastatic disease on imaging studies (which is clearly noted in hospital/clinical records) and progression on ADT alone between 01 January 2016 and 31 December 2018 4. Availability of medical records at the participating site reflecting at least one LOT received in the mCRPC setting and 12 months of follow-up from the index date (unless the patient died or was lost to follow-up within the first 12 months after diagnosis)
Exclusion
- Patients with a concomitant cancer at the time of diagnosis of mCRPC or those who are treated with any anti-cancer therapy indicated for other cancers within 6 months of diagnosis of mCRPC, except for non-metastatic non-melanoma skin cancers or in situ or benign neoplasms.
- 2\. Patients unable to give an informed consent (unless a waiver is granted)
Key Trial Info
Start Date :
September 28 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 30 2022
Estimated Enrollment :
1920 Patients enrolled
Trial Details
Trial ID
NCT04801186
Start Date
September 28 2021
End Date
September 30 2022
Last Update
September 7 2023
Active Locations (30)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Valledupar, Colombia, 200005
2
Research Site
Alexandria, Egypt, 21500
3
Research Site
Cairo, Egypt, 11517
4
Research Site
Cairo, Egypt, 11522